Lakewood-based KRTL Holding Group Inc. has successfully registered Industria Químico Farmaceutica SIGMA CORP. S.R.L. (SIGMA) with the U.S. Food and Drug Administration’s (FDA) Federal Establishment Identifier (FEI). This milestone underscores the collaboration between KRTL and SIGMA in enhancing regulatory readiness and gaining access to the U.S. market.
Bolivia, known for its biodiversity and natural resources, presents opportunities in the pharmaceutical sector. The partnership highlights Bolivia’s potential as a hub for pharmaceutical innovation and manufacturing. The U.S. Department of Commerce has noted that “Bolivia presents untapped potential in the development of pharmaceutical manufacturing and export capabilities, offering a promising avenue for partnerships and investments.”
This achievement allows Bolivian pharmaceutical products to enter the global market. SIGMA is recognized as a leader in Bolivia’s pharmaceutical industry, embodying the country’s goal of improving its manufacturing and export capabilities. KRTL and SIGMA seek to leverage Bolivia’s resources to produce high-quality pharmaceuticals that meet U.S. standards.
“This registration represents a transformative step in positioning Bolivian-manufactured pharmaceuticals for global opportunities,” said Cesar Herrara, CEO of KRTL Holding Group Inc. “Bolivia’s wealth of natural resources and innovative potential create a unique foundation for growth. Our partnership with SIGMA reflects KRTL’s commitment to fostering sustainable development and advancing access to healthcare solutions worldwide.”
The companies aim to introduce Bolivian products to international markets and pave the way for the future of Bolivia’s pharmaceutical exports.
The collaboration between KRTL and SIGMA is focused on establishing Bolivia’s pharmaceutical sector as a global competitor. By merging SIGMA’s manufacturing capabilities with KRTL’s regulatory expertise, they are promoting economic growth and creating pathways for Bolivian pharmaceuticals in new markets.
KRTL and SIGMA plan to expand production capacity, adopt advanced pharmaceutical technologies and target additional global markets. These initiatives reflect their commitment to enhancing Bolivia’s healthcare infrastructure while contributing to the international pharmaceutical landscape.
